In advanced pancreatic cancer, it is highly unlikely that POLE mutations contribute to genetic instability; therefore, POLE mutations do not serve as a relevant biomarker and should not be tested for on a regular basis (51). Here, POLE is linked to familial pancreatic carcinoma.